Activity Chair:
Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC
Director of Preventative Cardiology
CGH Medical Center
Sterling, IL
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, IL
Professor of Clinical Medicine
Michigan State University College of Osteopathic Medicine
East Lansing, MI
Adjunct Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD
Steering Committee:
Sergio Fazio, MD, PhD
The William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine, Physiology and Pharmacology
Director, Center of Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
Michael Miller, MD, FACC, FAHA
Professor of Medicine, Epidemiology and Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Cardiology Division
Baltimore, MD
Pamela B. Morris, MD, FACC, FACP, FACPM, FAHA, FNLA*
Chair, Prevention Leadership Council, American College of Cardiology
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina
Charleston, SC
Reviewers:
Jerome D. Cohen, MD
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP (Recertification review on 1/11/2018)
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.
Activity Chair and Steering Committee reports the following relationship(s) which are accurate at the time of original content release (February 24, 2016):
Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC
Consulting Fee: Amarin, Amgen, AstraZeneca, Atherotech, Genzyme, Kowa, Merck, LipoScience, Novartis, Regeneron
Speakers Bureau: Amarin, AstraZeneca, GSK, Kowa, Merck
Sergio Fazio, MD, PhD
Consulting Fee: Amarin, Genentech, Genzyme, ISIS, Lupin, Merck, Roche, Sanofi
Michael Miller, MD, FACC, FAHA
Consulting Fee: Amarin, Amgen, Pfizer
Contracted Research: Amgen, Eli Lilly
Pamela B. Morris, MD, FACC, FACP, FACPM, FAHA, FNLA
Consulting Fee: Amgen, AstraZeneca
Contracted Research: Amgen
Reviewers report the following relationship(s):
Jerome D. Cohen, MD
No relevant financial relationships to disclose.
Ronald Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.